New hope for tough breast cancer: testing drug combo before surgery
NCT ID NCT07283692
Summary
This study is testing whether adding a new immunotherapy drug (serplulimab) to standard chemotherapy before surgery helps shrink tumors more effectively in people with triple-negative breast cancer. It will involve about 46 women with early-stage disease to see if this combination leads to no detectable cancer at surgery and is safe. The goal is to improve treatment outcomes for this aggressive cancer type.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, 200127, China
Conditions
Explore the condition pages connected to this study.